Form 4: Zimmer Biomet Director Acquires Phantom Stock Units as Part of Deferred Compensation Plan

Maria Teresa Hilado, a Director at Zimmer Biomet Holdings, Inc., acquired 370.431 phantom stock units on June 30, 2025, as part of her deferred compensation plan.

Summary

• Maria Teresa Hilado, a Director of Zimmer Biomet Holdings, Inc. (ZBH), acquired 370.431 phantom stock units.
• The transaction occurred on June 30, 2025.
• These units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• Each phantom stock unit has a conversion or exercise price of $91.11 and converts on a 1-for-1 basis to common stock.
• Following this transaction, Maria Teresa Hilado beneficially owns 10,505.352 phantom stock units.
• The units are to be settled in cash in ten annual installments, beginning within sixty days after the end of the calendar year in which her service as a Director ceases.

Sentiment

Score: 5

Explanation: The document is a routine SEC Form 4 filing disclosing a director's acquisition of phantom stock units as part of a deferred compensation plan, which is a neutral event with no immediate positive or negative implications for the company's operational or financial performance.

Positives

• The acquisition of phantom stock units aligns the director's interests with long-term shareholder value through a deferred compensation plan.
• The deferred compensation plan provides a structured mechanism for director remuneration.

Negatives

• No specific negative aspects are indicated in this routine compensation disclosure.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

Phantom stock units are scheduled to be settled in cash through ten annual installments, commencing within sixty days after the end of the calendar year in which the reporting person's service as a Director ceases.

Industry Context

This Form 4 filing details a routine compensation event for a director within the medical technology industry, specifically for a company specializing in musculoskeletal healthcare. Such deferred compensation plans are common mechanisms for aligning director incentives with long-term company performance across various industries.

Comparison to Industry Standards

• The use of phantom stock units as a component of non-employee director compensation is a common practice among publicly traded companies, including those in the medical device and healthcare sectors, such as Stryker Corporation (SYK) or Johnson & Johnson (JNJ), which often utilize equity-based or equity-linked compensation to align director interests with shareholder value.
• Deferred compensation plans, allowing directors to defer receipt of compensation, are also standard in corporate governance, providing tax efficiency and long-term retention incentives.

Corporate Governance

Related Party Transactions

• The acquisition of phantom stock units is part of the "Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors," which is a standard compensation arrangement between the company and its director.

Stakeholder Impact

• Shareholders: The transaction represents a routine compensation event for a director, aligning their long-term interests with the company's performance through equity-linked compensation.
• Employees, Customers, Suppliers, Creditors: No direct or significant impact on these stakeholders is indicated by this compensation disclosure.

Next Steps

• Settlement of the phantom stock units in cash, in ten annual installments, commencing within sixty days after the end of the calendar year in which Maria Teresa Hilado's service as a Director ceases.

Key Dates

Keywords

Zimmer Biomet Holdings, ZBH, SEC Form 4, Insider Trading, Phantom Stock Units, Deferred Compensation, Director Compensation, Maria Teresa Hilado, Equity Compensation